TITLE

A cancer drug based on a tumor-killing virus has for the first time succeeded in a late-stage clinical trial, giving a lift to a technology that has long tantalized doctors and researchers

PUB. DATE
March 2013
SOURCE
MondayMorning;3/25/2013, Vol. 21 Issue 11, p1
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article offers information on the success of a cancer drug based on a tumor-killing virus in the Phase 3 clinical trial in patients with advanced melanoma. It mentions that the drug is being developed by the drug manufacturing company Amgen Inc. It includes that 16 percent of the patients who had the treatment, called talimogene laherparepvec (TVEC) in the trial, observed a significant shrinkage of their tumors.
ACCESSION #
86435143

 

Related Articles

  • European Conference of Clinical Oncology. Boggs, Jennifer // BioWorld Today;9/26/2007, Vol. 18 Issue 187, p3 

    The article reveals the results of a biomarker analysis conducted by Amgen Inc. for the use of KRAS as a predictive clinical biomarker for patients who are likely to response to Vectibix monotherapy. The analysis demonstrated that the effect of Vectibix on progression-free survival was confined...

  • Good to the Bone: Denosumab Shines Again in Phase III Data. Osborne, Randy // BioWorld Today;9/22/2009, Vol. 20 Issue 182, p1 

    The article reports on the results of Phase III clinical trials for Amgen Inc.'s denosumab for breast cancer patients. It presents a comparison between denosumab and Novartis AG's Zomer in tumors. It reveals the progression-free survival results for denosumab according to analyst Christopher J....

  • Amgen edges up on trial results. Investor's Business Daily // Investors Business Daily;8/29/2014, pA02 

    The biotech firm edged up 0.6% to 138.69 after reporting positive results from its phase three trial of evolocumab in combination with statins in Japanese patients.

  • Melanoma vaccines show promise. Josefson, Deborah // BMJ: British Medical Journal (International Edition);03/14/98, Vol. 316 Issue 7134, p800 

    Details the clinical trials for vaccines developed to fight melanoma. Procedure used in the trials; Findings of the trials.

  • A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma. Poschke, Isabel; Lövgren, Tanja; Adamson, Lars; Nyström, Maria; Andersson, Emilia; Hansson, Johan; Tell, Roger; Masucci, Giuseppe; Kiessling, Rolf // Cancer Immunology, Immunotherapy;Oct2014, Vol. 63 Issue 10, p1061 

    Adoptive transfer of in vitro-expanded tumor-infiltrating lymphocytes (TIL) has shown great clinical benefit in patients with malignant melanoma. TIL therapy itself has little side effects, but conditioning chemo- or radiotherapy and postinfusion interleukin 2 (IL-2) injections are associated...

  • Amgen: Phase 3 results for melanoma therapy successful.  // Hem/Onc Today;5/25/2013, Vol. 14 Issue 10, p18 

    The article reports on the success of the clinical trial conducted by researchers at Amgen on the efficacy and safety of talimogene laherparepvec, an investigational oncolytic immunotherapy, compared to subcutaneous granulocyte-macrophage colony-stimulating factor for advanced unresected melanoma.

  • Cardiology.  // CenterWatch Weekly;1/13/2014, Vol. 18 Issue 2, p10 

    The article reports that Amgen Inc. has released results of a clinical trial of evolocumab for high cholesterol treatment.

  • Ardelyx Raises $30M Series B For Lead Drug RDX5791 Trials. Wall, Tom // BioWorld Today;9/1/2011, Vol. 22 Issue 170, p1 

    The article reports the 30 million U.S. dollar Series B preferred stock financing raised by Ardelyx Inc., creator of small molecule drug. It notes that this financing will be used to fund the completion of an ongoing Phase II trial of RDX5791 drug that involves 180 patients with...

  • Amid Low Expectations, Aranesp Trial Fails to Show Heart Benefit. Young, Donna // BioWorld Today;8/27/2009, Vol. 20 Issue 165, p1 

    The article reports on the results of the Phase III trial of Aranesp, a darbepoetin alfa from Amgen Inc. Called Trial to Reduce Cardiovascular Endpoints With Aranesp Therapy (TREAT), the study found that the drug did not significantly lessen incidents of heart attack and other cardiovascular...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics